Identification of FDA-Approved Drugs with Activity against Stationary Phase Bartonella henselae.

Li T, et al. Antibiotics (Basel). 2019.


Bartonella henselae can cause various infections in humans, ranging from benign and self-limiting diseases to severe and life-threatening diseases as well as persistent infections that are difficult to treat. To develop more effective treatments for persistent Bartonella infections, in this study, we performed a high-throughput screen of an FDA-approved drug library against stationary phase B. henselae using the SYBR Green I/propidium iodide (PI) viability assay. We identified 110 drug candidates that had better activity against stationary phase B. henselae than ciprofloxacin, and among the top 52 drug candidates tested, 41 drugs were confirmed by microscopy to have higher activity than the current frontline antibiotic erythromycin.

The identified top drug candidates include:

  • pyrvinium pamoate
  • daptomycin
  • methylene blue
  • zole drugs (clotrimazole, miconazole, sulconazole, econazole, oxiconazole, butoconazole, bifonazole)
  • aminoglycosides (gentamicin and streptomycin, amikacin, kanamycin)
  • amifostine (Ethyol)
  • antiviral Lopinavir/ritonavir
  • colistin
  • nitroxoline
  • nitrofurantoin
  • verteporfin
  • pentamidine
  • berberine
  • aprepitant
  • olsalazine
  • clinafloxacin
  • clofoctol

Pyrvinium pamoate, daptomycin, methylene blue, clotrimazole, and gentamicin and streptomycin at their respective maximum drug concentration in serum (Cmax) had the capacity to completely eradicate stationary phase B. henselae after 3-day drug exposure in subculture studies.

While the currently used drugs for treating bartonellosis, including rifampin, erythromycin, azithromycin, doxycycline, and ciprofloxacin, had very low minimal inhibitory concentration (MIC) against growing B. henselae, they had relatively poor activity against stationary phase B. henselae, except aminoglycosides.

The identified FDA-approved agents with activity against stationary phase B. henselae should facilitate development of more effective treatments for persistent Bartonella infections.



I am convinced that Bartonella is a much bigger player in Lyme/MSIDS than we are being led to believe. Just type Bartonella into the search bar on this website and you will see what I mean.  It’s everywhere, and people without cat exposure who are perfectly healthy are getting it. 

And it with Lyme and it’s a, “one, two, punch, you are out!”

I’m so thankful to see this work being done on drug effectiveness as it is desperately needed.

Interesting personal side-note: when we relapse it is Bartonella symptoms. Recently, I’ve relapsed twice while my husband didn’t.  Guess what he just started taking that I’m not?  Berberine for thick blood.  Berberine is one of the substances listed above.  Bizzarely, Berberine comes from the woody part of the Barberry plant – the thorny, invasive shrub that ticks love to live under. Now if that isn’t Ironic, I don’t know what is.  Excerpt:

Barberry has a stronger form of Berberine, according to some experts, than what’s found in Goldenseal, Coptis, or golden thread and the Oregon Grape and is used in both Indian and Chinese medicine.  Master herbalist, Steven Buhner states it is active against a large number of resistant bacteria and numerous strains of Mycoplasma, a common coinfection of Lyme.

Berberine is a chemical found in several plants including European barberry, goldenseal, goldthread, Oregon grape, phellodendron, and tree turmeric:

Do not take Berberine without discussing it with your pracitioner.  There are contraindications.

Seems it does many things:




%d bloggers like this: